and albiglutide, a once-weekly GLP-1 peptide that could be a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. The diabetes and cardiovascular markets are expansive, and darapladib and albiglutide could
Prescriptions for Amylin 's breadwinner Byetta have declined ..... entrench Victoza in the market. We think Amylin will have a hard time returning to top-line ..... basis for both Byetta and Bydureon, but Amylin lacks a composition-of-matter patent
AstraZeneca AZN announced the acquisition of Amylin AMLN for $31 per share in an all-cash deal. Amylin 's board of directors unanimously recommended ..... tender their shares, so we plan to raise our Amylin fair value estimate to $31 as we don't
Amylin AMLN saw stagnant sales and its net loss widen during first quarter ..... keeping our fair value estimate in place, which reflects Amylin 's value on a stand-alone basis. Amylin reported net product sales of $150.6 million in first-quarter
albiglutide could also hit the market within the next few years as a more convenient alternative to Novo Nordisk's NVO and Amylin 's AMLN competing diabetes products. Human Genome stands to receive royalties on worldwide sales of both products, should they become
(Reuters) - Shares of Amylin Pharmaceuticals Inc rose 12 percent in premarket trade following a Reuters report that the drug maker is seeking buyers after it spurned a $3.5 billion buyout offer from...
Shares of Amylin Pharmaceuticals AMLN skyrocketed Tuesday as it was revealed ..... our current fair value estimate for Amylin , which values the company on a stand-alone ..... what we would expect a biotech of Amylin 's size and prospects to fetch
years in front of the Food and Drug Administration, Amylin AMLN and partner Alkermes finally succeeded in clinching approval ..... diabetes drug Bydureon, the once-weekly version of Amylin 's GLP-1 mimetic Byetta. We plan to raise our fair
We are putting Amylin Pharmaceuticals AMLN under review following the company's ..... exenatide franchise and the viability of Amylin itself has dramatically increased ..... projected modest contributions from Amylin -partnered products, and Lilly's
(Reuters) - Shares of Amylin Pharmaceuticals Inc climbed more than 15 percent in heavy trading on Thursday, a day after the U.S. health regulator approved wider use of its diabetes drug Byetta.